S100B and Parkinson disease: Current evidence suggests a time-specific role of S100B in PD, with higher levels seen in earlier disease states and normalized levels seen years later [65]: serum autoantibodies against S100B were shown to be four times higher in PD patients five years post-diagnosis, with antibody levels decreasing to typical baseline values ten years after diagnosis [30].